Cagrilintide vs Tirzepatide
Metabolic
Cagrilintide
Long-acting amylin analog studied at calcitonin and amylin receptors — a satiety pathway mechanistically distinct from incretin agonism.
Metabolic
Tirzepatide
Dual GIP and GLP-1 receptor agonist — a 39-amino-acid synthetic peptide studied for combined incretin pathway activity.
Side by side
| Dimension | Cagrilintide | Tirzepatide |
|---|---|---|
| Molecular weight | 4409 g/mol | 4813.45 g/mol |
| Size class | long peptide | long peptide |
| CAS number | 1415456-99-3 | 2023788-19-2 |
| Research area | metabolic | metabolic |
| Sequence | Not published as a linear sequence | Not published as a linear sequence |
| Available sizes | 10mg | 10mg, 20mg, 30mg |
| Entry price | $99 | $89 |
| Cost per mg | $9.90 | $6.63 |
Mechanism
Cagrilintide
Cagrilintide is an acylated analog of human amylin, the peptide co-secreted with insulin from pancreatic β-cells. It acts at the calcitonin receptor and amylin receptor subtypes, a pathway entirely separate from GLP-1 and GIP signaling. Research interest centers on whether amylin and incretin pathways are additive, which is why it appears frequently in combination studies alongside semaglutide.
Tirzepatide
Tirzepatide is a synthetic 39-amino-acid peptide engineered from the native GIP sequence with structural modifications conferring agonism at both the GIP and GLP-1 receptors. A C20 fatty diacid moiety supports albumin binding and extended half-life. Its research interest lies substantially in the question of whether dual incretin agonism produces effects distinguishable from GLP-1 monoagonism.
Evidence quality
Mechanism is not the same as evidence. Where we have assessed the literature, the verdict is stated plainly.
Tirzepatide
Evidence base: strong receptor-level characterization and independent replication; GIP receptor directionality remains genuinely contested.
Full research reference →Research applications
Cagrilintide
- Amylin and calcitonin receptor binding studies
- Combination pharmacology with incretin agonists
- Satiety signaling research in preclinical models
- Gastric emptying rate assays
Tirzepatide
- Dual incretin receptor signaling and biased agonism studies
- Comparative studies against selective GLP-1 agonists
- cAMP accumulation and β-arrestin recruitment assays
- Adipose and hepatic metabolic pathway research
Common questions
What is the difference between Cagrilintide and Tirzepatide?
Cagrilintide is long-acting amylin analog studied at calcitonin and amylin receptors — a satiety pathway mechanistically distinct from incretin agonism. Tirzepatide is dual GIP and GLP-1 receptor agonist — a 39-amino-acid synthetic peptide studied for combined incretin pathway activity. They differ in molecular weight (4409 vs 4813.45 g/mol) and in the pathways they are studied against.
Which is more cost-effective per milligram, Cagrilintide or Tirzepatide?
Tirzepatide is lower at approximately $6.63 per milligram at its best tier, against $9.90 for the other. Cost per milligram is only meaningful relative to the concentrations a given protocol requires, since these compounds are not used at comparable masses.
Can Cagrilintide and Tirzepatide be studied together?
Combination designs appear in the published literature for a number of these compounds. Whether it is appropriate for a given protocol depends entirely on the model and endpoint. We supply research compounds and do not provide protocol guidance — consult the primary literature for your specific model.
How should Cagrilintide and Tirzepatide be stored?
Store lyophilized at -20°C protected from light. Reconstituted at 2-8°C for up to 30 days. For Tirzepatide: Store lyophilized powder at -20°C protected from light. Reconstituted solution stable at 2-8°C for up to 30 days.
Which has the stronger evidence base?
Tirzepatide — Evidence base: strong receptor-level characterization and independent replication; GIP receptor directionality remains genuinely contested. Where we have not published a formal evidence assessment, treat the literature as requiring your own appraisal.
All products are intended strictly for laboratory research use. Not for human or veterinary use. Not for diagnostic or therapeutic use. Not a drug, food, or cosmetic.
Comparison generated from NuVida Vital catalog data. Every specification is reconciled against the certificate of analysis for the shipped batch.